Sleepiness and the Effects of CPAP on Salivary Cortisol and Alpha-Amylase Levels in Patients With Sleep Apnea

Completed · Not applicable · Has a placebo group

Conditions studied: Sleep Apnea, Sleep Disordered Breathing

In brief

Patients with Obstructive Sleep Apnea Syndrome (OSAS) will evidence higher levels of salivary cortisol and alpha-amylase levels prior to use of placebo and continuous positive airway pressure (CPAP) and will evidence a decrease in these levels after consistent use of continuous positive airway pressure (CPAP) therapy as compared to placebo. Their level of sleepiness will also decrease with the use of CPAP therapy and will correlate with the levels of salivary cortisol and alpha-amylase in relation to their subjective sleepiness scale, Psychomotor Vigilance Test (PVT), and pupillometry.

Key facts

Study ID

NCT01196117

Run by

Medical College of Wisconsin

People needed

18

Starts

2004-11-15

Expected to finish

2011-12-15

Last updated by the study team

2020-04-01

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults
• Male and female
• Between ages 18 and 90
• Undergo a Polysomnography (PSG) with evidence of any sleep disordered breathing including snoring, mild/moderate/severe sleep apnea, and/or restless legs

You may not qualify if…

• Ages 17 and under
• Pregnant women

Where it is running

• Froedtert West Clinics - Otolaryngology Clinc — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.